Scenic Immunology BV has disclosed glutaminyl-peptide cyclotransferase (QPCT; QC) and/or glutaminyl-peptide cyclotransferase-like protein (QPCTL; isoQC) inhibitors reported to be useful for the treatment of cancer.
Empyrean Therapeutics Inc. has acquired a first-in-class TLR2 antagonist molecule from Eos Therapies Inc. with the aim of treating brain, pancreatic, breast and other hard-to-treat cancers.
Researchers from Astrazeneca plc presented the discovery and preclinical characterization of AZD-9793, a novel CD8-guided T-cell engager (TCE) being developed for the treatment of hepatocellular carcinoma (HCC).
Researchers from Pyxis Oncology Inc. presented preclinical data for PYX-201, an antibody drug conjugate (ADC) that targets extra domain B of fibronectin (EDB+FN).
Anocca AB has submitted its first clinical trial application (CTA) to the EMA for a phase I/II multi-asset umbrella trial, VIDAR-1. The application covers ANOC-001 as the initial product in the VIDAR-1 program targeting mutated KRAS in advanced pancreatic cancer.
Radiopharmaceutical company Telix Pharmaceuticals Ltd. has inked a deal worth up to AU$264 million (US$171 million) to license and develop next-generation radiopharma imaging and therapy technology targeting fibroblast activation proteins found in a wide range of cancers.
Hebei Wutu Pharmaceutical Co. Ltd. has synthesized transient receptor potential cation channel subfamily V member 4 (TRPV4) antagonists reported to be useful for the treatment of liver cancer, cirrhosis, hepatic fibrosis, chronic hepatitis B and liver failure.
Beijing Danatlas Pharmaceutical Technology Co. Ltd. has disclosed poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
J Ints Bio Co. Ltd. has announced research findings with JIN-001, in development in collaboration with MD Anderson Cancer Center, for the treatment of brain tumors.
Researchers from Cogent Biosciences Inc. have presented data on their PI3KA H1047R mutant inhibitor CGT-6297 PI3KA wild-type inhibitors can lead to toxicity issues such as hyperglycemia, gastrointestinal toxicity and skin reactions.
RSS
